In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

US FDA eliminates REMS for autologous chimeric antigen receptor CAR T cell immunotherapies: Maryland Monday, June 30, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FD ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...